SCHEMBL4097097

SCHEMBL4097097

O=C(Nc1ccc(OC(F)(F)F)cc1)Nc1cccc(C(=O)Nc2ccccc2C(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.56
▸ KMT2A Q03164 3/20 0.56
▸ PKM P14618 1/20 0.56
▸ GRIK1 P39086 1/20 0.56
▸ IGF2BP2 Q9Y6M1 1/20 0.54
▸ EPHX2 P34913 2/20 0.53
▸ FAAH O00519 1/20 0.53
▸ TP53 P04637 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ CASP3 P42574 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ SENP7 Q9BQF6 1/20 0.53
▸ RXFP1 Q9HBX9 3/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ KCNK2 O95069 1/20 0.50
▸ KCNK10 P57789 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4087804 0.84 TRPA1 (0.54) MEN1KMT2APKMIGF2BP2MAPT
SCHEMBL4087797 0.84 TRPA1 (0.54) MEN1KMT2APKMIGF2BP2MAPT
SCHEMBL12171071 0.84 EPHX2 (0.69) MEN1KMT2AEPHX2FAAHTP53
SCHEMBL14855642 0.79 KMT2A (0.79) MEN1KMT2APKMGRIK1MAPT
SCHEMBL22103767 0.79 EPHX2 (0.86) MEN1KMT2AEPHX2FAAHTP53
SCHEMBL3150329 0.77 RXFP1 (0.59) GRIK1RXFP1
SCHEMBL10833844 0.77 MEN1 (0.63) MEN1KMT2APKMIGF2BP2MAPT
SCHEMBL4097163 0.77 KCNK9 (0.72) MEN1KMT2APKMTP53RXFP1
SCHEMBL26154100 0.76 EPHX2 (0.71) MEN1KMT2AEPHX2FAAHTP53
SCHEMBL2562031 0.76 TRPV1 (0.75) MEN1KMT2AEPHX2FAAHHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 — — US disclosed
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 — — US disclosed
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 — — US disclosed
EP-1758571-A1 CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE 7TM Pharma A/S (DK) 2007-03-07 — — EP disclosed
WO-2005115374-A1 CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE 7TM PHARMA A/S (DK) 2005-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use NR1H2, NR1H3, HRH2 MEN1 2859/4885KMT2A 2570/4885PKM 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback